Merck Balks At Class Bid In Fosamax Case

Law360, New York (September 17, 2007, 12:00 AM EDT) -- Already facing a mountain of suits over Fosamax, Merck has protested a recent bid for certification of a dental monitoring class for patients taking the osteoporosis drug, arguing that the group has been unable to make a case that would justify the move.

On Friday, lawyers for Merck & Co. Inc. filed their objection in the U.S. District Court for the Southern District of New York, contending that plaintiffs’ recent request for class certification would be an inappropriate remedy under the law.

“Plaintiffs seek unprecedented class...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.